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ABSTRACT: A variety of features of autism can be simulated in
rodents, including the core behavioral hallmarks of stereotyped and
repetitive behaviors, and deficits in social interaction and communi-
cation. Other behaviors frequently found in autism spectrum disor-
ders (ASDs) such as neophobia, enhanced anxiety, abnormal pain
sensitivity and eye blink conditioning, disturbed sleep patterns, sei-
zures, and deficits in sensorimotor gating are also present in some of
the animal models. Neuropathology and some characteristic neuro-
chemical changes that are frequently seen in autism, and alterations
in the immune status in the brain and periphery are also found in
some of the models. Several known environmental risk factors for
autism have been successfully established in rodents, including ma-
ternal infection and maternal valproate administration. Also under
investigation are a number of mouse models based on genetic
variants associated with autism or on syndromic disorders with
autistic features. This review briefly summarizes recent develop-
ments in this field, highlighting models with face and/or construct
validity, and noting the potential for investigation of pathogenesis,
and early progress toward clinical testing of potential therapeutics.
Wherever possible, reference is made to reviews rather than to
primary articles. (Pediatr Res 69: 34R–40R, 2011)
There are a number of difficulties in developing animalmodels with features of autism. First, the disorder is
currently defined by a set of core behavioral abnormalities
rather than by objective biomarkers. Moreover, two of the
core features, deficits in social interaction and in communica-
tion, can only be approximated in rodent studies (1). Second,
autism may actually represent a set of behaviorally distinct
disorders, with different causes and divergent pathogenesis
(2). Use of the broader definition, autism spectrum disorders
(ASDs), further compounds this problem. Third, the genetics
of autism is complex, encompassing numerous candidate
genes, copy number variations (CNVs), and monogenic, syn-
dromic disorders that display autistic symptoms (3). Fourth,
there is currently no pathognomic feature of autism that can be
assayed in animals that can be used clearly distinguish, for
instance, an “autistic mouse” from a “schizophrenic mouse”
(4). Despite these obstacles, animal research has progressed
rapidly in recent years, and a subset of the numerous proposed
models display many of the characteristic features of autism,
at least as they can be assayed in animals.
Behaviors in mice and rats can be directly related to the three
core symptoms of autism as follows: i) deficits in social interac-
tion (e.g. 3 chamber assay or analysis of videotapes), ii) deficits
in communication [e.g. ultrasonic vocalizations (USVs) or scent
marking], and iii) increased repetitive/stereotyped motor behav-
iors (e.g. self grooming or marble burying) and insistence on
sameness and restricted interests (e.g. neophobia, perseveration
in the T maze or water maze) (1). Rodents can also be tested for
a number of other behaviors found in subsets of ASD subjects
such as enhanced anxiety and eye blink conditioning, and a
deficit in sensorimotor gating [prepulse inhibition (PPI)]. A neu-
ropathology characteristic of autism, a spatially localized deficit
in Purkinje cells, is also found in certain mouse models.
Environmental Risk Factors
Maternal infection. A large epidemiological study using
the Danish Medical Register recently confirmed and strongly
extended previous studies that suggested maternal infection as
a risk factor for autism in the offspring. An examination of
more than 10,000 autism cases found a significant association
with maternal viral infection in the first trimester (5). Rodent
models of this risk factor include maternal respiratory infec-
tion with influenza virus and maternal immune activation
(MIA) with either polyinosine:cytosine [poly(I:C)], a syn-
thetic, double-stranded RNA that evokes an antiviral-like
immune reaction, or lipopolysaccharide (LPS), which evokes
an antibacterial-like immune reaction. The poly(I:C) MIA
model has been extensively studied with regard to the behav-
ior of the offspring, and their neuropathology, neurochemistry,
structural MRI, and more recently electrophysiology (4,6,7).
Depending on the GA at which MIA or infection is adminis-
tered, these offspring can be studied in the context not only of
autism but also schizophrenia, because maternal infection is a
well-characterized risk factor for the latter disorder as well (8).
Poly(I:C) MIA offspring exhibit behaviors similar to the core
symptoms of autism: deficits in social interaction and com-
munication (USVs), and increased repetitive/stereotyped mo-
tor behaviors (self-grooming and marble burying, and perse-
veration in the water maze, Refs. 4 and 7 and unpublished
data). These offspring also display a number of other behav-
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iors found in subsets of ASD subjects such as neophobia,
enhanced anxiety and eye blink conditioning, and a deficit in
PPI (Refs. 4 and 6 and unpublished data). A characteristic
autism neuropathology, spatially localized deficit in Purkinje
cells, is also present in the offspring of infected mothers (9),
and poly(I:C)-induced MIA causes other histopathological
changes similar to those seen in autism (4,6,10,11). At the
same time, features characteristic of schizophrenia are also
present: enlarged ventricles, alterations in dopaminergic neu-
rochemistry, and some of the behavioral abnormalities are
postpubertal in onset and are ameliorated by antipsychotic
drugs (4,6). Recent electrophysiological studies have revealed
synaptic changes within the hippocampus and in its commu-
nication with the prefrontal cortex (12–14).
Maternal LPS administration yields offspring with some
of the same features, and a few of the abnormal behaviors
can be reversed by antipsychotic drug treatment (4). Neu-
ropathology in the LPS model ranges from severe to very
mild, depending on the treatment protocol (4,7,15). Some
of these effects, such as increased cell density and limited
dendritic arbors in the hippocampus, have been found in
autism. Electrophysiological recordings reveal reduced
synaptic input to CA1 of the hippocampus, heightened
excitability of pyramidal neurons, enhanced postsynaptic
glutamatergic responses, and impaired NMDA-induced
synaptic plasticity (4,16,17).
Taken together, these findings demonstrate that the mater-
nal infection and MIA models display face (similar symp-
toms) and construct (similar cause) value for both autism and
schizophrenia. These models may have predictive value as
well. Several types of perturbation can ameliorate the adverse
effects of MIA on the offspring. For instance, pretreatment of
pregnant rats with N-acetyl-cysteine, which increases calcium
influx when binding to glutamate receptors in combination
with the transmitter, and also suppresses fetal inflammatory
responses to LPS, prevents many of the effects of maternal
LPS (17–19). Changing the balance of cytokines can also
block MIA effects. A single injection of IL-6 in pregnant mice
induces many of the behavioral abnormalities in the offspring
seen with poly(I:C) injection. Conversely, injection of the
mother with an anti-IL-6 antibody blocks the effects of
poly(I:C), and poly(I:C) injection in IL-6 knockout (KO)
mothers yields normal offspring (20). Moreover, the elevation
in maternal IL-6 causes an inflammatory imbalance in the
placenta, which leads to endocrine changes that are likely to
be detrimental to the fetus (21) (Fig. 1). There is also severe
placental inflammation when pregnant rats are given a high
dose of LPS, and this reaction can be blocked by administra-
tion of an IL-1 receptor antagonist (22). Administration of the
anti-inflammatory cytokine IL-10 prevents fetal loss and
white-matter damage following uterine bacterial infection.
Elevation of IL-10 also has a protective effect in pregnant
mice given LPS or poly(I:C) (4). An attractive feature of this
potential therapeutic is that endogenous IL-10 is essential for
resistance to LPS-induced preterm labor and fetal loss. Thus,
administration of this cytokine enhances the natural protective
mechanism. However, increased IL-10 in the absence of MIA
in pregnant mice can lead to behavioral abnormalities in the
adult offspring (23), a finding likely related to the fact that
normal human pregnancy involves increased inflammation
(24,25).
Postnatal cytokine perturbations are a safer potential ther-
apeutic approach. A preliminary study of the thiazolidinedi-
one, pioglitazone, which has anti-inflammatory properties,
causes a significant decrease in irritability, lethargy, stereo-
typy, and hyperactivity in autistic children, with greater effects
Figure 1. Summary of MIA-induced effects on the placenta. Maternal injection of poly(I:C) activates the maternal immune system, elevating proinflammatory
factors, including IL-6, which enters the spiral arteries that descend through the decidua and spongiotrophoblast layers, filling the maternal bloodspaces of the
labyrinth. Resident immune cells in the decidua are activated to express CD69 and further propagate the inflammatory response. IL-6 derived from decidual cells
acts in a paracrine manner on target cells in the spongiotrophoblast layer. Ligation of the cognate receptor IL-6Ra to gp130 leads to JAK/STAT3 activation and
increases in acute phase proteins, such as SOCS3, and down-regulation of placental growth hormone (GH) production. This leads to reduced IGF-binding protein
3 (IGFBP3) and IGFI. Global changes in STAT3 activation in the spongiotrophoblast layer alter the production of placenta-specific prolactin protein (PLP) and
other PLPs. These changes in endocrine factors very likely lead to acute placental pathophysiology and subsequent effects on fetal development. Reprinted from
Hsiao EY and Patterson PH Brain Behav Immun, in press; Copyright © 2010 Elsevier, Ltd., with permission.
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on younger patients (26). MIA models provide an attractive
platform for further testing of such therapies. It is also clear
that postnatal cytokine manipulations can induce behavioral
changes in the absence of MIA (27).
Valproic acid. Another model with construct and face
validity involves maternal valproic acid (VPA; valproate)
administration. The offspring of women taking this medication
for mental illness or epilepsy during early pregnancy are at
elevated risk for autism (7,28,29). In pregnant rats, a single
injection of VPA results in behavioral abnormalities such as
increased stereotypic/repetitive behavior, decreased social in-
teraction, altered sensitivity to sensory stimuli, impaired PPI,
elevated anxiety, impaired reversal learning, altered eye blink
conditioning, and enhanced fear memory processing, all of
which are consistent with autism and are also found in MIA
offspring (4,29). It is interesting that maternal VPA exposure
leads to reduced expression of neuroligin (NLGN) (30), an
autism candidate gene that is described below. Electrophysi-
ological studies indicate that VPA offspring exhibit abnormal
microcircuit connectivity (31), which may be related to MRI
studies showing impaired long-range functional connectiv-
ity in autism. Recordings in the lateral amygdaloid nucleus
suggest molecular and synaptic alterations in VPA mice
that are relevant for the alterations in amygdala morphol-
ogy and behavior in autism (32). There are also immune
abnormalities such as decreased weight of the thymus,
decreased splenocyte response to stimulation, and a lower
IFN/IL-10 ratio. Most of these abnormalities are found
only in male offspring, which is consistent with the male
bias in autism incidence (29).
The key mechanisms underlying the effects of maternal VPA
on fetal brain development are unclear at present, primarily
because this molecule has a wide range of activities, including
altering gene expression, cell death, and immune dysregulation.
Although maternal VPA exposure is responsible for only a
tiny fraction of autism cases, this syndrome, together with the
maternal infection risk factor, provides abundant proof-of-
principle for environmental influences on autism incidence.
Moreover, the similarities in neuropathology and behavior be-
tween the rodent models and human autism support the utility of
environment-based models for defining relevant pathways of
developmental dysregulation. A next step is to test the gene-
environment paradigm by asking whether the effects of maternal
VPA or MIA can be exacerbated in mice carrying genetic
variants associated with increased risk for autism. In one inter-
esting experiment, such offspring were raised under conditions of
environmental enrichment (EE), in which rodents are reared in
groups in relatively large enclosures, with a wide variety of
objects to explore, and running wheels on which to exercise.
Compared with VPA offspring raised under standard housing
conditions, treating VPA offspring for just 1 wk with EE results
in significant improvements in anxiety, stereotyped behaviors,
social interaction, and PPI (33). It is striking that in this experi-
ment, the therapeutic effects of EE administered during the rat
equivalent of childhood were able to last through adulthood.
Genetic Models
A number of different types of genetic modifications can
increase the risk for developing ASD or autistic symptoms.
Monogenic syndromes can involve core autistic symptoms and a
variety of other serious conditions (tumors, physical malforma-
tions, etc.) that are not found in ASD. There are also several rare
Mendelian mutations and de novo chromosomal deletions or
duplications (CNVs) that cause ASD. Many of these mutations
and CNVs cause a broader phenotype than that found in idio-
pathic autism. There are a great many mouse models for this
diverse array of genetic variants and, given space limitations,
only a few can be described briefly here.
FMR1. Fragile X syndrome (FXS) is caused by mutations
in the FMR1 gene on the X chromosome. The disorder shares
a number of symptoms in common with autism, mental retar-
dation, attention deficit hyperactivity disorder, and epilepsy.
Fmr1 KO mice display some core behavioral features of
autism including impaired social interaction and repetitive
behavior. Expression of other autism-related symptoms such
as anxiety and hyperactivity depends on the genetic back-
ground (34). A 50% reduction of metabotropic glutamate
receptor 5 (mGluR-5) expression in these mice normalizes
dendrite morphology, seizure susceptibility, and inhibitory
avoidance extinction. The mGluR theory of FXS proposes that
up-regulation of group I mGluR causes exaggerated protein
synthesis-dependent functions, which underlie the neuropa-
thology and behavioral traits associated with FXS (35).
FXS seems to be one of several ASD-related disorders that
exhibit an imbalance between excitation and inhibition in
Figure 2. A social network for autism susceptibility candidate genes. Anal-
ysis of the relationships between 33 autism candidate genes (red emblems)
and associated syndrome genes (green emblems) was performed using the
Ingenuity pathway analysis. Direct (solid lines) and indirect (dashed lines)
associations between the candidate genes demonstrate the close relationships
between these genes. Recently published interactions linking FMR1, CYFIP1,
and JAKMIP1 by gene regulation, and A2BP1 (FOX1) with NLGN-3 by
splicing regulation were added as custom interactions (blue lines). The
androgen receptor (orange emblem) and three of its interactions with candi-
date genes (orange lines) are highlighted to demonstrate the correlation with
the extreme male brain hypothesis. Reprinted from Bill BR and Geschwind
DH Curr Opin Genetics Devel 19:271–278; Copyright 227 2010 Elsevier,
Ltd., with permission.
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brain circuitry. In the case of FXS, experiments in an Fmr1
KO model indicate that there is too much excitation, which
leads to deficits in cognitive function. In a Drosophila model,
lowering the level of excitation with a drug that inhibits
binding of a common excitatory neurotransmitter to its recep-
tor rescues memory deficits and defective courtship behavior
and structural abnormalities in the CNS. The ability to rescue
some of the behaviors by treatment in the adult suggests that
rectifying the excitatory/inhibitory imbalance is enough for
restoration of function even with possible defects in the wiring
patterns caused during development. Moreover, a similar
pharmacological treatment in the adult mouse KO reverses
anxiety in the open field and susceptibility to seizures (36).
These results formed the basis of small, open-label clinical
trials using medications that have effects similar to those
tested in the mice. These trials yielded positive results, im-
proving a variety of deficits in the patients, and still unpub-
lished results from one double blind trial are said to be
positive. Clinical trials are also underway to test two other
types of medications, unrelated to the excitatory/inhibitory
balance, but which work well in FXS animal models (36).
MeCP2. Rett syndrome (RTT) is another genetic disorder
that displays a wide variety of symptoms, some of which
resemble those found in autism. The patients, who are almost
entirely females, seem to develop normally for 6–18 mo, but
this is followed by ASD symptom onset, severe mental retar-
dation, seizures, and features highly characteristic of RTT
such as stereotyped hand movements, abnormal breathing,
motor deficits, and scoliosis. The mutations causing the dis-
ease are in the gene, methyl-CpG-binding protein (MeCP2). In
the female mouse model of MeCP2 disruption, the mice seem
normal until about 16 wk of age (a mouse typically is mature
by 4 wk and dies at 2–3 y). Behavioral deficits in these mice
include enhanced anxiety in the open field, reduced nest
building, and aberrant social interactions. Genetic background
modifies learning and memory performance (37). Mice over-
expressing MeCP2 also develop a progressive neurological
disorder with, surprisingly, an enhancement in synaptic plas-
ticity and motor and contextual learning skills between age 10
and 20 wk, and, at an older age, hypoactivity, seizures, and
abnormal forelimb clasping, all of which are reminiscent of
human RTT (37). Although this time course certainly indi-
cates a regression, it does not resemble the time course of the
regressive form of autism or of RTT.
Remarkably, restoring MeCP2 expression in a conditional
KO model in immature or even in mature mice results in
reversal of the disease phenotype, as measured by behavioral
and electrophysiological tests (38). Thus, despite the fact that
MeCP2 function was disrupted during fetal and postnatal
development, several disease symptoms can be reversed. In a
test of a potential treatment based on a growth factor defi-
ciency observed in RTT, administration of an active peptide
fragment of IGF 1 to MeCP2 mutant mice extends life span,
improves locomotor, heart and breathing functions, and stabi-
lizes a measure of cortical plasticity (38). Synaptic dysfunc-
tion can also be achieved by increasing the level of another
growth factor, brain-derived neurotrophic factor (39). A clin-
ical trial testing IGF-1 in patients with RTT began in 2009.
Still another intriguing approach for RTT is EE, which im-
proves several aspects of the disease phenotype. Moreover,
levels of brain-derived neurotrophic factor and IGF-1 are
increased by EE (40). Although EE does not restore normal
behavior or lifespan to the RTT mice, it does induce some
significant positive effects.
Tuberous sclerosis. Tuberous sclerosis (TSC) is a genetic
disease with ASD symptoms in which mutations in one of two
TSC genes cause multiple, benign tumors to grow in various
tissues including the brain. Hamartin and tuberin, the protein
products of TSC1 and TSC2, inhibit mammalian target of
rapamycin (mTOR) (41). Interestingly, mTOR signaling is
dysregulated in the FMRP-deficient mouse (42). In addition,
as in MeCP2 mutant mice, the Tsc2/ KO mouse model
responds to treatment in adulthood. Brief administration of the
mTOR inhibitor rapamycin rescues synaptic plasticity and the
behavioral deficits in the TSC model (43). Moreover, early
phase clinical trials suggest that cognitive features of TSC
may be reversible in adult humans (44).
Although it is thought that autism can result from an environ-
mental stimulus acting on a susceptible genetic background, little
has been published on this issue thus far. Thus, it is important that
Tsc2/mice display a social interaction deficit only when they
are born to mothers treated with poly(I:C) (45). That is, this
deficit is most severe when the MIA environmental risk factor is
combined with a genetic defect that, in humans, also carries a
high risk for ASD. In addition, there is an excess of TSC-ASD
individuals born during the peak influenza season, an association
that is not seen for TSC individuals not displaying ASD symp-
toms (45).
Neuroligin-3 and -4. Several rare, causal variants in the
NLGN-3 and -4 genes are associated with ASD (46). These
postsynaptic proteins, which, together with their presynaptic
and intracellular binding partners, the -neurexins and
SHANK3, respectively, are involved in synaptic maturation
and transmission. One missense mutation in NLGN-3 and -4
missense and two nonsense mutations in NLGN-4 have been
identified in a small number of individuals with ASDs (46),
supporting the hypothesis that synaptic dysfunction is impor-
tant in ASDs. Mutations in neurexin and SHANK3 are also
found in ASD probands, but whether they are involved in
ASD etiology is controversial (47). The KO for Shank1, the
closest relative to Shank3, exhibits increased anxiety, im-
paired contextual fear memory, and, surprisingly, enhanced
performance in a spatial learning task but impaired memory
retention of that task (48). Additional behavioral results rele-
vant to the core autism symptoms have yet to be reported.
Results with NLGN-3 and -4 mutant mice support the
functional significance of NLGNs in synaptic function and
social behavior. A NLGN-3 knockin (KI) mouse with a point
mutation in the endogenous mouse gene that is identical to the
relevant human NLGN-3 gene (49) displays increased inhibi-
tory synaptic transmission without a change in excitatory
transmission, a phenotype not observed in Nlgn-3 KO mice,
emphasizing the disparity between missense and nonsense
mutations. The enhanced inhibitory synaptic transmission in
Nlgn-3 KI mice is accompanied by a deficit in social interac-
tion and, as observed in the Shank1 KO, enhanced spatial
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learning ability. These results are surprising because individ-
uals with mutations in NLGN-3 and -4 do not exhibit poten-
tiated learning skills. It is of potential therapeutic interest that
administration of the NMDA receptor partial coagonist (and
anti-inflammatory agent) D-cycloserine can rescue the exces-
sive grooming behavior in adult Nlgn-1 KO mice (50).
Although Nlgn-4 KO mice display abnormalities in two of
the three core autistic symptoms, reciprocal social interaction
and impaired USV communication, they do not seem to
display repetitive behavior or impairments in some of the
other autism symptoms such as sensory sensitivity, sensori-
motor gating, locomotion, exploratory activity, anxiety, or
learning and memory (51). These observations are consistent
with those seen in patients with the NLGN-4 mutation, who
also do not show these comorbid features. To summarize, several
NLGN models exhibit strong construct validity, and the face
validity of the Nlgn-4 KO is fairly good at the behavioral level
but much remains to be done on its neuropathology.
Contactin-associated protein-like 2. A well-validated ASD
susceptibility gene is contactin-associated protein-like 2
(CNTNAP2), which is a member of the neuronal neurexin
superfamily that is involved in neuron-glial interactions and is
likely to be important in brain development (52). It is intrigu-
ing that CNTNP2 expression is elevated in circuits in the
human cortex that are important for language development.
Moreover, its expression is elevated in song nuclei required
for vocal learning in the zebra finch, and this is male specific,
as is the song behavior (53). In addition, CNTNP2 polymor-
phisms are associated with language disorders, and the ex-
pression of this gene can be regulated by FOXP2, mutations in
which can cause language and speech disorders (54). In light
of these associations, it is important that the Cntnap2 KO
mouse has a deficit in USVs and social interaction, and
displays repetitive behaviors. These mice also exhibit several
other features of ASD: seizures, mild cortical laminar disor-
ganization, and hyperactivity (Geschwind DG, unpublished
data).
Oxytocin and Vasopressin. Pharmacological and genetic
manipulations of oxytocin (OT) and vasopressin (AVP) have
unequivocally established the importance of these neuropep-
tides in the regulation of complex social behaviors. Moreover,
functional alterations in these systems may contribute not only
to social deficits in autism but also to repetitive behaviors
(55,56). For instance, reduced OT plasma levels are observed
in autistic children, and OT receptor (OTR) mRNA is de-
creased in postmortem autism temporal cortex. Conversely,
intranasal infusion of OT reduces stereotypic behavior and
improves eye contact and social memory in high functioning
autistic patients. Moreover, genetic variations in OTR and
AVP receptor V1aR can be associated with autism.
However, the face value of the OT and AVP KO mice for
studying features of autism mixed. Adult Ot KO mice display
reduced anxiety, a finding inconsistent with autism. In addi-
tion, compared with WT, both Ot and Otr KO males emit
fewer USVs in the pup isolation test, which is suggestive of
decreased anxiety during maternal separation but is also con-
sistent with the lack of communication in ASD. The Ot KO
mice fail to recognize familiar conspecifics on repeated social
encounters, although olfactory and nonsocial memory are
intact (1,55,56). This has been interpreted as an autism-like
social deficit, although social amnesia has not been described
in autism. Comprehensive neuropathology remains to be re-
ported in these strains. Given the implications for ASD in the
human findings, further study of Ot mutant mice is warranted,
although striking species differences are apparent for OT and
AVP, and their receptors (55).
Male V1ar KO mice exhibit deficits in olfactory social
recognition and social interaction (1,55). Similar to Ot and Otr
KO mice, V1ar KO mice show reduced anxiety-like behavior.
No deficits in learning and memory or in PPI are detected.
V1br KO adult females emit fewer USVs in a resident-intruder
test. Although the number of USVs emitted by infant mutants
is not affected during the conventional pup separation test,
mutant pups fail to display maternal potentiation of USVs,
which could suggest either a defect in a cognitive component
or reduced anxiety (1). Thus, as for OT mice, the face value of
Avpr KO mice is mixed.
BTBR. The BTBR mouse strain has been studied carefully
at the behavioral level and also displays a striking neuroana-
tomical feature. Compared with several other mouse strains,
BTBR mice exhibit low levels of sociability and abnormal
social learning in the transmission of food preference test.
Moreover, BTBR mice show a high level of spontaneous
repetitive grooming, poor shift performance in a hole-board
task, and a deficit in the water maze reversal task, which can
be interpreted as the resistance to change in routine that is
observed in autism (1,57). BTBR pups emit more and longer
USVs in comparison with C57 pups. Their repertoire of
vocalization is also narrower in comparison with pups from
standard mouse strains. However, one might expect to see
lower rates of USVs in pups if modeling the ASD communi-
cation deficit. Such a deficit is reported in adult BTBR mice
(1). Detailed study of the fine structure of USVs, as well as
their behavioral functions in young and adult mice, is an
important area for future studies of animal models of psychi-
atric disease.
Compared with C57 mice, BTBR mice display an exagger-
ated response to stress that is associated with high blood levels
of corticosterone (58). Such enhanced stress could cause or
aggravate the behavioral phenotype of these mice. Key ana-
tomical features of BTBR mice are the absence of the corpus
callosum and a reduced hippocampal commissure (1). Overall,
a number of BTBR behaviors are consistent with autism, and
the most striking anatomical feature in this strain is consistent
with many, but not all, studies of the corpus callosum in
autism (59).
A difficulty with this line is that comparisons are necessarily
made with other, unrelated mouse lines, and it is not clear to
which lines BTBR should be compared. For instance, similar
to BTBR mice, but unlike C57 mice, BALB/c mice display
low social behavior, reduced USVs, and reduced empathy-like
behavior (1). Because there are many genetic differences
between such strains, comparing their behaviors is not equiv-
alent to comparing behaviors and neuropathology between
mutant and WT mice of the same genetic background. None-
theless, the search for the genes causing behavioral pheno-
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types is ongoing, and a single nucleotide polymorphism in
KMO, which encodes kynurenine 3-hydroxylase, has been
found in BTBR mice when compared with unrelated strains
(1). This enzyme regulates the synthesis of kynurenic acid, a
neuroprotective molecule whose levels are abnormal in other
neuropsychiatric diseases, including schizophrenia.
Perspectives
Several of the genetic models and both types of environ-
mental risk factor models discussed here display some or all
the core behavioral features of autism. In general, the analysis
of neuropathology and electrophysiology is at a more ad-
vanced stage in the environmental models. Much remains to
be done regarding the immune status of the models, and the
state of the gastrointestinal tract, which can be disturbed in
ASD (60,61). The animal work has not yet shed light on the
mysterious strong male bias found in autism prevalence. Much
remains to be done to characterize the types and social func-
tions of USVs in rodents. Approaches toward understanding
the Theory of Mind deficit in autism using rodents are just
beginning, using assays for empathy (1), for instance. Another
frontier is represented by intriguing nonhuman primate mod-
els based on immune manipulation and maternal infection
(62,63).
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